Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02542293
Title	Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)
Acronym	NEPTUNE
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung non-small cell carcinoma
Therapies	Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab + Tremelimumab Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	USA \| GBR